Search

Your search keyword '"Pane, Marika"' showing total 946 results

Search Constraints

Start Over You searched for: Author "Pane, Marika" Remove constraint Author: "Pane, Marika"
946 results on '"Pane, Marika"'

Search Results

2. Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study

4. Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome?

5. The IAAM LTBP4 Haplotype is Protective Against Dystrophin-Deficient Cardiomyopathy.

6. Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy

8. Assessing Prevalence and Characteristics of Oro-bulbar Involvement in Children and Adults with SMA Type 2 and 3 Using a Multimodal Approach

9. Genetic modifiers of upper limb function in Duchenne muscular dystrophy.

10. Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA

11. Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module

12. Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study

14. Patient reported outcome measure for upper limb in Duchenne muscular dystrophy: correlation with PUL2.0.

15. Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping

16. Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies

17. Genetic modifiers of respiratory function in Duchenne muscular dystrophy.

18. Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening

19. Assessing floppy infants: a new module

21. Body mass index in type 2 spinal muscular atrophy: a longitudinal study

22. Long term follow-up of scoliosis progression in type II SMA patients

23. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial

24. Expanding the clinical-pathological and genetic spectrum of RYR1-related congenital myopathies with cores and minicores: an Italian population study

27. Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study.

28. Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes

29. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial

30. Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen

31. The nonsense mutation stop+4 model correlates with motor changes in Duchenne muscular dystrophy

32. The Spinal Muscular Atrophy Health Index: Italian validation of a disease-specific outcome measure

33. Ultrasound assisted versus landmark based intrathecal administration of nusinersen in adults with spinal muscular atrophy disease: A randomized trial.

34. The emerging spectrum of neurodevelopmental comorbidities in early-onset Spinal Muscular Atrophy

35. De Novo DNM1L Mutation in a Patient with Encephalopathy, Cardiomyopathy and Fatal Non-Epileptic Paroxysmal Refractory Vomiting.

36. Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3.

37. Validation and cross‐cultural adaptation of the Italian version of the paediatric eating assessment tool (I‐PEDI‐EAT‐10) in genetic syndromes.

38. Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen

39. Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study

40. Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data

42. The emerging spectrum of neurodevelopmental comorbidities in early-onset Spinal Muscular Atrophy

44. Genotype–phenotype correlations in recessive titinopathies

47. Contactless: a new personalised telehealth model in chronic pediatric diseases and disability during the COVID-19 era

48. MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients

49. Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen

50. 2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants

Catalog

Books, media, physical & digital resources